MGMT and glioblastoma: Promoter status of the MGMT has been established as a strong clinically relevant factor in glioblastoma patients, the mandatory testing of this biomarker in routine practice is however highly controversial, because insufficient data were by far available to justify a direct conclusion between MGMT status testing and individual treatment choice, especially for younger patients.[39] In a post hoc analysis of the EORTC 26981 trial [6], the combination of RT and TMZ conferred a modest but significant survival benefit in younger patients (<70 years) who had an unmethylated MGMT promoter.